iiinova — where your digital self keeps evolving

Reposted by Elizabeth Plimack MD

Cris Bergerot, PhD @crisbergerot.bsky.social · 15/02/2025

Exploring the burden of cancer in metastatic renal cell carcinoma (mRCC) 📊🧬 This study sheds light on the impact of mRCC on patients & healthcare systems. Don’t miss these key insights @ascocancer.bsky.social #GU25!

021

Reposted by Elizabeth Plimack MD

Tian Zhang, MD @tiansterzhangmd.bsky.social · 14/02/2025

#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25

0104

Reposted by Elizabeth Plimack MD

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 15/02/2025

On my way back home from #ascoGU25 Great discussion yesterday by @ERPlimackMD of #CheckMate 274 / #NIAGARA in the context of perioperative + adjuvant immunotherapy in #bladdercancer @oncodaily.bsky.social @oncoalert.bsky.social

0123

Reposted by Elizabeth Plimack MD

Nima Sharifi MD @nimasharifimd.bsky.social · 15/02/2025

Why is funding NIH so important? Listen to the Good News About Cancer w/ @charlesryanmd.bsky.social @mskcancercenter.bsky.social @drkarenknudsen.bsky.social & Dr. Morgans. Also amazing news about decline in lung cancer in Puerto Rico b/c of public health measures! podcasts.apple.com/us/podcast/4...

podcasts.apple.com

4.75 Million Lives Saved, and Counting

Podcast Episode · The Good News About Cancer · 02/11/2025 · 23m

064

Elizabeth Plimack MD @erplimackmd.bsky.social · 15/02/2025

Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...

083

Reposted by Elizabeth Plimack MD

David Aggen, MD @davidaggen.bsky.social · 15/02/2025

Fantastic to see @IyerGopa showing updated data from FGFR3 inhibitor Loxo-435 with ORR of 41% DCR 90% 50% (6/12 patients) confirmed responses with prior FGFR3 inhibitor @MSKCancerCenter #ASCOGU #GU25

032

Reposted by Elizabeth Plimack MD

Tian Zhang, MD @tiansterzhangmd.bsky.social · 14/02/2025

@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25

183

Reposted by Elizabeth Plimack MD

Ravi Madan @ravimadan.bsky.social · 13/02/2025

Watching #BCR session @asco #GU25 it is very clear there is a drive to treat #BCR asap esp w/+ #PSMA But there is no data supporting a curative strategy & in that context deferring therapy max’ing #QOL is quite reasonable given JHU MFS data below ascopubs.org/doi/10.1200/...

141

Reposted by Elizabeth Plimack MD

American Society of Clinical Oncology @ascocancer.bsky.social · 10/02/2025

Announcing the ASCO Genitourinary Cancers Symposium Featured Voices! Follow along for a range of expert insights and join the conversation using the official hashtag: #GU25 Not yet registered? There’s still time to join us in person or online: brnw.ch/21wQAYk

0114

Reposted by Elizabeth Plimack MD

Ravi Madan @ravimadan.bsky.social · 10/02/2025

As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer www.nature.com/articles/s41...

053

Reposted by Elizabeth Plimack MD

Philadelphia Eagles @philadelphiaeagles.bsky.social · 10/02/2025

SUPER BOWL CHAMPIONS! THIS ONE’S FOR YOU PHILLY!

494154162868

Reposted by Elizabeth Plimack MD

Sen. Adam Schiff @schiff.senate.gov · 08/02/2025

Trump & Musk are making massive cuts to the National Institutes of Health. I know there is a lot going on right now, but this is one of worst things they have done so far, will affect cancer research and trials, the search for cures, innovation and competitiveness, our universities. Your lives.

46747601212

Reposted by Elizabeth Plimack MD

Wafik S. El-Deiry, MD, PhD, FACP @weldeiry.bsky.social · 09/02/2025

Both ERA Commons and NIH Reporter are currently unavailable.

101

Reposted by Elizabeth Plimack MD

Oncology Brothers @oncbrothers.bsky.social · 06/02/2025

🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25: - Bladder Ca - Prostate Ca - RCC *Join us LIVE* 📅 Date: Feb 12, 2025 ⏰ Time: 6:00-8:00PM 📝 bit.ly/guaio25 #OncSky #MedSky #gusm #Oncology #Cancer #CanSky

071

Reposted by Elizabeth Plimack MD

NEJM.org @nejm.org · 26/01/2025

In the ESOPEC trial, researchers evaluated whether perioperative chemotherapy improves overall survival as compared with preoperative chemoradiotherapy in patients with resectable esophageal adenocarcinoma. Full trial results and Plain Language Summary: nej.md/4apWlo5 #MedSky #Oncology

The New England Journal of Medicine
Perioperative Chemotherapy in Esophageal Cancer
A PLAIN LANGUAGE SUMMARY

Illustration of resectable esophageal adenocarcinoma.

Read the full Plain Language Summary at NEJM.org.

0192

Reposted by Elizabeth Plimack MD

NEJM.org @nejm.org · 06/12/2024

Hello, #MedSky community! We’re excited to begin our Bluesky journey. Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

32860187

Reposted by Elizabeth Plimack MD

Alex Knapp @thealexknapp.bsky.social · 27/01/2025

Hello out there scientists. If you're having meetings or grants or anything else impacted by freeze of NSF meetings, please feel free to reach out to me to share your story. Signal: thealexknapp.79 Email: aknapp@forbes.com

13909422

Reposted by Elizabeth Plimack MD

European Medicines Agency @ema.europa.eu · 27/01/2025

🎉 EMA celebrates its 3️⃣0️⃣th anniversary highlighting its evolving role at the centre of the EU assessing & authorising safe, high-quality medicines for 450 million people & countless animals in Europe. Learn more about EMA’s key achievements over the past 30 years: www.ema.europa.eu/en/news/ema-...

ema.europa.eu

EMA celebrates 30 years of progress in science and medicines in the European Union | European Medicines Agency (EMA)

Agency marks milestone highlighting its changing role in Europe

34544104

Reposted by Elizabeth Plimack MD

Adam Grant @adamgrant.bsky.social · 26/01/2025

The clearest sign of intellectual chemistry isn’t agreeing with someone. It’s enjoying your disagreements with them. Harmony is not the combination of identical sounds. It’s the pleasing arrangement of different tones, voices, or instruments. Creative tension makes beautiful music.

481776233

Reposted by Elizabeth Plimack MD

Tian Zhang, MD @tiansterzhangmd.bsky.social · 23/01/2025

Creating a bladder & kidney cancer starter pack of friends and colleagues here in @bsky.app! Please comment if you want to be added! bsky.app/start/did:pl... @pgrivasmdphd.bsky.social @drchoueiri.bsky.social @erplimackmd.bsky.social @davidaggen.bsky.social @pcvblack.bsky.social

6114

Elizabeth Plimack MD @erplimackmd.bsky.social · 25/01/2025

Thanks Esther for this explainer, I hope it reaches the right audience. The complexity of health research is not widely appreciated, yet the diseases scientists are trying to cure affect us all.

1153

Reposted by Elizabeth Plimack MD

Alexander Kutikov, MD, FACS @uretericbud.bsky.social · 04/01/2025

Thrilled to announce that my dear friend and colleague, Jay Simhan, MD, FACS, has been named Chair of Urology at Temple University Hospital! I’m thrilled to partner as two departments under the Fox Chase-Temple Urologic Institute to elevate our already world-class program to even greater heights!

0102

Reposted by Elizabeth Plimack MD

Tian Zhang, MD @tiansterzhangmd.bsky.social · 26/12/2024

This Christmas and every year I remember my current and past patients with ornaments on our tree. Have been fortunate to care for thousands in my ten year career in oncology. Hope to help thousands more in the years to come. 🎄🕯️

082

Reposted by Elizabeth Plimack MD

Yüksel Ürün @yukselurun.bsky.social · 18/12/2024

Can some MIBC patients safely skip cystectomy? In a phase II trial, 48% of biomarker-selected patients on active surveillance post-AMVAC avoided cystectomy without metastasis. 2-yr MFS: 73%. @oncoalert.bsky.social @oncbrothers.bsky.social @erplimackmd.bsky.social doi.org/10.1200/JCO-...

1185

Reposted by Elizabeth Plimack MD

Ravi Madan @ravimadan.bsky.social · 09/12/2024

#PSMA imaging is showing #ProstateCancer in a WAY never seen before but it is unlikely to be showing Prostate Cancer that we have never encountered before The presumption of the latter leads to aggressive therapy which may not be required More data on this coming from @theNCI

free-url-shortener.rb.gy

Free URL Shortener | Powered by Rebrandly

Free URL Shortener for transforming long, ugly links into nice, memorable and trackable short URLs. Use it to shorten links | Powered by Rebrandly

071

Reposted by Elizabeth Plimack MD

David Y.T. Chen @dytcmd.bsky.social · 07/12/2024

Another memorable night. #SUO24 reunion (credit @urocorrea.bsky.social ) bringing together the extended FCCC family, and introducing future YUO/SUO colleagues. To alums who couldn’t make it, we hope to see you #AUA25 in Vegas, baby!

Great turnout for #SUO24 FCCC reunion. Here we capture the crowd towards the end of the night. Awesome to see back multiple years of alums (Teper ‘12, Mehrazin/Tomaszewski ‘14, Waingankar ‘16, Ristau ‘17, Correa/Joshi ‘18, Bernstein/Strother ‘21, Ginsburg/Schober ‘22, Wang ‘24) AB has the bonus of being asked more than 1x where she is a resident and can be mistaken as a current applicant. The FCCC training proof of impact: PDs at Emory and Mt. Sinai and YUOs coming up who were trainees of our alums. Fox Chase Proud!

082

Reposted by Elizabeth Plimack MD

Bryan Carmody @jbcarmody.bsky.social · 05/12/2024

Percentage of available positions that filled in yesterday’s fellowship match.

Bar chart demonstrating the percentage of fellowship positions filled, by specialty, in the NRMP Fellowship Match on December 4, 2024. In cardiology, hematology-oncology, GI, and rheumatology, 99% of positions filled. In pediatric nephrology, just 37%, and in child abuse pediatrics, just 33% of positions were filled.

1212540

Reposted by Elizabeth Plimack MD

pgrivasmdphd.bsky.social @pgrivasmdphd.bsky.social · 06/12/2024

Stayed active during 17-hour flight from SEA->Singapore :-) Looking forward to present TROPiCS04 phase 3 trial data at #ESMOASIA on Dec 7 ~10am local time discussed by Dr. Friedlander @oncoalert.bsky.social @achoud72.bsky.social @erplimackmd.bsky.social @valdesan.bsky.social @fredhutch.bsky.social

172

Reposted by Elizabeth Plimack MD

HCWvsHunger @hcwvshunger.bsky.social · 05/12/2024

🥳🥳🥳 The final results of the 2024 #HCWvsHunger competition have been confirmed & certified! Most exciting: #MedTwitter & supporters have raised a total of $3,155,425 to fight #FoodInsecurity since the first annual competition in 12/20!! /1 cc @tmprowell.bsky.social @shematologist.bsky.social

211734

Reposted by Elizabeth Plimack MD

David Y.T. Chen @dytcmd.bsky.social · 04/12/2024

Q&A—how to apply ctDNA in medical management—differing approaches by the panel reflects lack of existing data on whether ready for prime time and if it shld lead to a change in care compared to using clinical/path alone. #blcsm #SUO24

021

Reposted by Elizabeth Plimack MD

Elizabeth Plimack MD @erplimackmd.bsky.social · 22/11/2024

Join the conversation on all things #bladdercancer #kidneycancer #prostatecancer and help grow the GU Oncology Starter Pack go.bsky.app/6NdMXmY

7219

Reposted by Elizabeth Plimack MD

Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 02/12/2024

Let's share some love for @theaacr.bsky.social here on Bluesky and get them more followers, more engagement, and more awareness of programs like the SSP: @rickbuck.bsky.social @ashi-w.bsky.social @johannajoyce.bsky.social @erplimackmd.bsky.social @pauladbos.bsky.social @anirbanmaitra.bsky.social

084

Reposted by Elizabeth Plimack MD

Emil Lou, MD, PhD, FACP, FASCO @cancerassassin1.bsky.social · 25/11/2024

De-escalation (of numbers of drugs as well as dosages) is shaping up to be a major theme in #oncology, beginning with @sabcs.bsky.social coming up next month. Colleagues in #breastcancer leading the way, maybe more to come for GI cancers at #GI25, and even more at #ASCO25?

0103

Reposted by Elizabeth Plimack MD

Julie Gralow @jrgralow.bsky.social · 23/11/2024

ASCO annual meeting 2025 abstract submitter open - closes Jan 28th. To support global innovation in cancer research, payment waivers offered to 1st authors from low- & lower-middle-income countries (World Bank)! Apply for a waiver when you submit an abstract conferences.asco.org/am/abstract-...

conferences.asco.org

ASCO Meetings

23722

Reposted by Elizabeth Plimack MD

Matt Cooperberg @dr-coops.bsky.social · 23/11/2024

ICYMI: *30* year outcomes from SPCG-4 dx.doi.org/10.1056/NEJM... RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm

14019

Reposted by Elizabeth Plimack MD

Ian Davis @profiand.bsky.social · 16/11/2024

GU starter pack… started! Let me know if you want to be added. go.bsky.app/DtoXvaD #Genitourinary #Oncology #GUonc #ProstateCancer #KidneyCancer #Urothelial #BladderCancer #PenileCancer #TesticularCancer #pcsm #kcsm #blcsm #tcsm #Medsky #Medtwitter

Genitourinary oncology starter pack

https://go.bsky.app/DtoXvaD

365420

Reposted by Elizabeth Plimack MD

Roland Dunbrack 🏳️‍🌈 @rolanddunbrack.bsky.social · 23/11/2024

I’m going to the Nobel prize celebrations in Stockholm in 2 weeks along w/100 other Rosetta contributors. I figure a few things we contributed were helpful in making it work in the pre-RF-diffusion days. Backbone-dependent scoring/sampling of rotamers helped design work, I think. Just got a new tux!

8934

Elizabeth Plimack MD @erplimackmd.bsky.social · 22/11/2024

Join the conversation on all things #bladdercancer #kidneycancer #prostatecancer and help grow the GU Oncology Starter Pack go.bsky.app/6NdMXmY

7219

Reposted by Elizabeth Plimack MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/11/2024

Old Twitter” refers to the platform’s earlier role as a hub where scientists could talk to one another, distribute and discuss preprints and published papers and communicate their research to the public. @tmprowell.bsky.social @erikahamilton9.bsky.social www.science.org/content/arti...

science.org

Like ‘old Twitter’: The scientific community finds a new home on Bluesky

After recent changes to Elon Musk’s X, a gradual migration turns into a stampede

1134

Reposted by Elizabeth Plimack MD

Alexander Kutikov, MD, FACS @uretericbud.bsky.social · 21/11/2024

Team lunch at Fox Chase 🙌 @dytcmd.bsky.social, you missed this one! @urocroll.bsky.social, nice hat!

3102

Reposted by Elizabeth Plimack MD

Yüksel Ürün @yukselurun.bsky.social · 21/11/2024

Active surveillance for intermediate-risk prostate cancer rose from 5% in 2010 to 12.3% in 2020. Most common in GG1 cases (53.8% by 2020). PSA and GG remain key factors. #ProstateCancer #ActiveSurveillance #Oncology #CancerResearch @oncoalert.bsky.social

1135

Reposted by Elizabeth Plimack MD

Ravi Madan @ravimadan.bsky.social · 16/11/2024

Ok Not really sure what I’m doing but this #ProstateCancer starter pack has been created It is meant to be INclusive so please let me know if you know anyone who wants so “join” @asharpmedonc.bsky.social @nimasharifimd.bsky.social @alison-tree.bsky.social @profiand.bsky.social go.bsky.app/ANw3D3j

233818

Reposted by Elizabeth Plimack MD

Ravi Madan @ravimadan.bsky.social · 20/11/2024

Responders to therapy do well. The real quandary is there something that is required to be done for #ProstateCancer pts w/out optimal response. Should be cautious about suboptimal responders abandoning effective therapy too quickly. Additional investigation is required. #TITAN

1144

Reposted by Elizabeth Plimack MD

Heather D @hldca.bsky.social · 19/11/2024

I've been in 7 #MetastaticBreastCancer treatment #ClinicalTrials and no one yet has shared the published results directly with me (I found articles via patient grps and that old place X). #Oncsky It really should be common practice and the UK's NHS agrees: www.hra.nhs.uk/planning-and...

hra.nhs.uk

Communicating study findings to participants: guidance

062